Tumor-secreted exosomal miR-141 activates tumor-stroma interactions and controls premetastatic niche formation in ovarian cancer metastasis

被引:0
作者
Yulan Mo
Leanne L. Leung
Celia S. L. Mak
Xueyu Wang
Wai-Sun Chan
Lynn M. N. Hui
Hermit W. M. Tang
Michelle K. Y. Siu
Rakesh Sharma
Dakang Xu
Stephen K. W. Tsui
Hextan Y. S. Ngan
Mingo M. H. Yung
Karen K. L. Chan
David W. Chan
机构
[1] The University of Hong Kong,Department of Obstetrics & Gynaecology, LKS Faculty of Medicine
[2] The University of Hong Kong,Centre for PanorOmic Sciences Proteomics and Metabolomics Core, Li Ka Shing Faculty of Medicine
[3] Shanghai Jiao Tong University,Faculty of Medical Laboratory Science, Ruijin Hospital, School of Medicine
[4] The Chinese University of Hong Kong,School of Biomedical Sciences
[5] The Chinese University of Hong Kong-Shenzhen,School of Medicine
来源
Molecular Cancer | / 22卷
关键词
miR-141; Hippo/YAP1/pathway; Ovarian cancer; Tumor-stroma interactions; Peritoneal metastases; cancer-associated fibroblasts;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 494 条
[71]  
Alexander J(2014)Elevated CXCL1 expression in breast cancer stroma predicts poor prognosis and is inversely associated with expression of TGF-beta signaling proteins BMC Cancer 14 781-undefined
[72]  
Cukierman E(2020)The many microenvironments of ovarian cancer Adv Exp Med Biol 1296 199-undefined
[73]  
Gyorgy B(2010)The chemokine CXCL1 induces proliferation in epithelial ovarian cancer cells by transactivation of the epidermal growth factor receptor Endocr Relat Cancer 17 929-undefined
[74]  
Szabo TG(2021)Epithelial-stromal communication via CXCL1-CXCR2 interaction stimulates growth of ovarian cancer cells through p38 activation Cell Oncol (Dordr) 44 77-undefined
[75]  
Pasztoi M(2000)Chemokine receptors CXCR-1/2 activate mitogen-activated protein kinase via the epidermal growth factor receptor in ovarian cancer cells J Biol Chem 275 6868-undefined
[76]  
Pal Z(2020)Tumor cells educate mesenchymal stromal cells to release chemoprotective and immunomodulatory factors J Mol Cell Biol 12 202-undefined
[77]  
Misjak P(2015)CXCR2 inhibition combined with Sorafenib improved antitumor and antiangiogenic response in preclinical models of ovarian Cancer PLoS One 10 e0139237-undefined
[78]  
Aradi B(2020)Inhibition of MDSC trafficking with SX-682, a CXCR1/2 inhibitor, enhances NK-cell immunotherapy in head and neck Cancer models Clin Cancer Res 26 1420-undefined
[79]  
Laszlo V(2017)Role of the CXCL8-CXCR1/2 Axis in Cancer and inflammatory diseases Theranostics 7 1543-undefined
[80]  
Pallinger E(2022)Combined inhibition of SHP2 and CXCR1/2 promotes antitumor T-cell response in NSCLC Cancer Discov 12 47-undefined